Neubewertung

Press releases 14 /09 /2009 Antisoma’s preliminary results for the year ended 30 June 2009 London , UK, and Cambridge, MA: 14
September 2009  Antisoma plc (LSE: ASM; USOTC: ATSMY) today  announces its preliminary results for the year ended 30  June 2009.
These results have been prepared under International Financial Reporting Standards (‘IFRS’) as adopted for use by the European Union. Highlights of 2008 /2009 ASA404  programme advances and expands Strong partnership maintained with Novartis Phase III trial in first-line lung cancer completes enrolment of 1200  patients (September 2009) Phase III trial in second-line lung cancer initiated Breast cancer selected as next indication for development AS1413  development gains momentum Phase III trial in secondary AML expanded Phase II trial shows durable responses in secondary AML AS1411  programme advances Positive data from phase II trial in AML Plans announced for phase IIb development in AML Phase II trial in renal cancer completes patient enrolment Value realised from oral fludarabine asset Drug approved by FDA Divested to sanofi-aventis in USD 65  million deal Strong cash position Oral fludarabine divestment extends cash runway to mid-2011 Cash life now extends beyond expected timing of key phase III data Cash and short-term deposits of GBP 67.0  million at 30  June 2009 Full-year loss of GBP 16.4  million Commenting on the results, Glyn Edwards, CEO of Antisoma, said:  "We have made important progress this year, with gathering momentum on our two phase III programmes, positive phase II data for a  third product and our first product approval from the FDA. With the pipeline maturing, we now have a dual focus on driving products towards regulatory approvals and on building a strong platform for  product commercialisation." Eric Dodd , Antisoma’s CFO, added:  "The successful divestment of oral fludarabine to sanofi-aventis has added significantly to our cash resources, further strengthening our balance sheet. We can now fund  all our priority programmes until mid-2011 , beyond the time we expect key phase III data for ASA404  and AS1413. " A webcast and conference call will be held today at 9 :30
am BST. The webcast can be accessed via  Antisoma’s website at  www.antisoma.com/asm/media/webcast/  and the call by dialling +44 (0)  207 806 1964  UK Toll (US Toll + 1
718 354 1390)  and using the Confirmation Code:  9656482.  A  recording of the webcast will also be available afterwards on the Antisoma website. Enquiries : Antisoma plc + 44 (0)7909 915 068 Glyn Edwards,  Chief Executive Officer Eric Dodd,  Chief Financial Officer Daniel Elger,  VP, Marketing & Communications       Buchanan Communications + 44 (0)20 7466 5000 (All media enquiries)   Mark Court, Lisa Baderoon       The Trout Group + 1 617 583 1308 (US investor enquiries)   Seth Lewis